WASHINGTON DC—A new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no other options to prevent the progress of this fatal phase of the disease. At the American Association for Cancer Research annual meeting Dr Daniel W. Lee from the Pediatric Oncology Branch of the National Cancer Institute in Bethesda, Maryland, presented findings from his group’s study using chimeric antigen receptor T-cell therapy, which involves removing T cells from the child, stimulating and genetically engineering them before re-infusing them in a primed state to fight the cancer. He discussed the clinical implications with Peter Goodwin.
You may also like...
Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia 24 Jan, 2014 First Line PARP Inhibition For Ovarian Cancer Assessed 2 Nov, 2018 ASCO Audio Journal of Oncology – May 1st, 2006 – In the company of Gordon McVie 1 May, 2006 Audio Journal of Oncology in Advance – March 1st, 2008 4 Mar, 2008
- Previous story Treating HER 2 positive metastatic breast cancer without chemotherapy?
- Next story Gene expression and molecular pathways guide head and neck cancer therapies
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014